Program
cariprazine
Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.
Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.
Drug pageCariprazine: every studyMany companies study it; this page follows only the 41 they lead. All 53 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 291 open or running | phase 3since Jan 27, 2010 | Nov 27, 2006 | Mar 2027phase 3 · NCT04777357 |
| Tanabe Pharmaits history only | 60 open or running | phase 3since Jun 19, 2012 | Mar 15, 2009 | none ahead |
| Gedeon Richter Plc.its history only | 21 open or running | phase 3since Jan 24, 2019 | Jun 13, 2014 | Dec 15, 2026phase 3 · NCT03817502 |
| Bostal Drug Deliveryits history only | 11 open or running | phase 3since Jul 15, 2026 | Jul 15, 2026 | Aug 2027phase 3 · NCT07722728 |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jul 1, 2026 | Jul 1, 2026 | none ahead |
| Mapi Pharma | 11 open or running | phase 2since Aug 28, 2025 | Aug 28, 2025 | Dec 31, 2026phase 2 · NCT07185815 |
| Whanin Pharmaceuticalits history only | 10 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | none ahead |
Also a collaborator on its studies: Gedeon Richter.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mapi Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 28, 2025First study: phase 2 study in SchizophreniaFirst studyNCT07185815 · 24 planned · India, Israel
Ahead
- Dec 31, 2026Primary completion: phase 2 study in SchizophreniaNCT07185815
TargetBeta
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| ABBV-932 | AbbVie | phase 2 | 10 |
Studies
The one study Mapi Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07185815Schizophrenia · India, Israel | 2 | Recruiting | Dec 31, 2026 | 24 |
How it is read
Names in the registry
- “Cariprazine”, 25 entries
- “MP-214 3mg”, 3 entries
- “MP-214 6mg”, 3 entries
- “MP-214 9mg”, 3 entries
- “MP-214”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 21 studies
- Depressive Disorder, Major, 6 studies
- Bipolar Disorder, 6 studies
- Mania, 3 studies
- Depression, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.